Metaplastic breast cancer with chondroid differentiation—case report and literature review

Author:

Leite Cláudia1,Dias Nuno2,Oliveira Domingos3,Mesquita Pinto Rita4,Cortez Vaz Francisco4

Affiliation:

1. General Surgery, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal

2. Pathology, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal

3. CEDAP, Centro de Diagnóstico Anatomo-Patologico, Coimbra 3000-377, Portugal

4. Gynecology and Obstetrics, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal

Abstract

Abstract Metaplastic breast cancer (MBC) comprises less than 1% of all breast cancers, and it is defined by a mixture of adenocarcinoma plus mesenchymal and epithelial components. It is more common in older and black female patients. It has a larger size and faster growth, and it is frequently node-negative and triple-negative when compared with invasive ductal carcinoma. The authors report the case of a 72-year-old female patient, presenting with a breast lump, whose biopsy revealed a probable MBC with chondroid differentiation. She underwent a breast conservative surgery (BCS) and axillary sentinel lymph node dissection (SLND). The pathological report was concordant with the biopsy, and the patient was proposed to chemoradiotherapy. Despite its rarity and more severe features at diagnosis, BCS plus SLND plus radiotherapy should be offered to these patients, associated with chemotherapy. Chondroid differentiation is the rarest of all histological subtypes.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Reference7 articles.

1. Breast cancer in the United States: a cross-sectional overview;Bilani;J Cancer Epidemiol,2020

2. Metaplastic breast cancer: prognostic and therapeutic considerations;Corso;J Surg Oncol,2021

3. Comparison of outcomes between metaplastic and triple-negative breast cancer patients;Polamraju;Breast,2020

4. When something seems amiss: radiology-pathology correlation of metaplastic breast cancer;Andreou;Cureus,2020

5. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1;Kalaw;Br J Cancer,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3